Clinical Trial

Evaluation of Non-Invasive Tests for Metabolic Liver Disease

Study acronym: NIMBLE
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 14, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers to diagnose and stage Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). MASH is characterized by liver inflammation accompanied by simultaneous fat accumulation in the liver.
Trial Details
NCT Number NCT07122700
Lead Sponsor Foundation for the National Institutes of Health
Conditions Metabolic Associated Fatty Liver Disease, Metabolic Associated Steatotic Liver Disease, Cirrhosis, Liver, NASH, Liver Fibrosis, Liver Fat, Liver Steatoses, Liver Inflammation
Enrollment 400 participants
Start Date 2025-05-13
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-14